IMMUNOFUTURE
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods. The company was founded in 2007 and is based in Tokyo, Japan.
IMMUNOFUTURE
Industry:
Biopharma Medical Pharmaceutical
Founded:
2007-03-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Status:
Active
Similar Organizations
Huvet Bio
Huvet Bio is engaged in the research and development of bio pharmaceuticals.
Current Employees Featured
More informations about "ImmunoFuture"
ImmunoFuture - Crunchbase Company Profile & Funding
Organization. ImmunoFuture . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... ImmunoFuture develops and researches drug discovery in …See details»
ImmunoFuture - Contacts, Employees, Board Members, Advisors …
Organization. ImmunoFuture . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. ImmunoFuture has 1 …See details»
Home - Vaccine and Infectious Disease Organization
Feb 21, 2025 Protecting the world from infectious diseases has never been more urgent. The Vaccine and Infectious Disease Organization (VIDO) is a global leader in infectious disease …See details»
Home Page - Canada’s Immunoengineering and Biomanufacturing …
Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH) is bringing together a coalition of partners to accelerate the development and manufacturing of lifesaving medicines …See details»
ImmunoFuture, Inc. - Products, Competitors, Financials, Employees ...
Provider of medical research-related services. Use the CB Insights Platform to explore ImmunoFuture, Inc.'s full profile.See details»
ImmunoFuture - Crunchbase
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods.See details»
Patents Assigned to ImmunoFuture, Inc. - Justia Patents Search
Justia Patents Patents Assigned to ImmunoFuture, Inc. Patents Assigned to ImmunoFuture, Inc. Drug Transporter Permeating Blood-Brain Barrier, Peptide and Use Thereof. Publication …See details»
ImmunoFuture, Inc. - Patent applications
ImmunoFuture, Inc. Patent applications: Patent application number Title Published; 20130337050: Drug Transporter Permeating Blood-Brain Barrier, Peptide and Use Thereof - A peptide, …See details»
Top 30 Innovative Immuno-Oncology Companies in the US: The
Understanding Immuno-Oncology and Its Role in Cancer Treatment. Immuno-oncology has emerged as a leading approach in cancer treatment, leveraging the body's immune system to …See details»
BioFuture | The New Age of Healthcare and Technology
The biopharma, digital health and healthcare sectors are undergoing profound change. BioFuture TM is a must-attend conference for anyone who wants to harness the evolution in the life …See details»
Immuno-Oncology Landscape - Cancer Research Institute
Landscape of Immuno-Oncology Drug Development. With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track …See details»
ImmunoFuture - Tech Stack, Apps, Patents & Trademarks
ImmunoFuture develops and researches drug discovery in infectious diseases and develops pharmaceuticals and treatment methods.See details»
Human Proteome Organization (HUPO) - Human Immuno …
Current lines of work: Organize a HUPO-HIPP summer school every two+ years to expand the immunopeptidomics community; Organize quarterly virtual webinars/panels to share and …See details»
Recommendations and guidelines for the treatment of infections …
Antimicrobial drug resistance is one of the major threats to global health. It has made common infections increasingly difficult or impossible to treat, and leads to higher medical costs, …See details»
Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity - PMC
Schematic description of the “inhibitory cytokine synergy” of TGF-β3 and IL-10 in activated B cells. Phosphorylation of S6 kinase 1 (S6K1) and expression of hypoxia inducible factor 1α …See details»
The Future of Cancer Diagnosis, Treatment and Surveillance: A …
Simplified schematic representation of the tumor microenvironment. (A) Schematic representation of immune cells in tumor microenvironment that have an anti-tumorigenic effect (natural killer …See details»
Kenki Taniguchi - CEO @ ImmunoFuture - Crunchbase Person Profile
Primary Organization . ImmunoFuture . Location Tokyo, Tokyo, Japan; Regions Asia-Pacific (APAC) Also Known As 谷口賢記; Kenki Taniguchi is the CEO of ImmunoFuture. Jobs. Edit …See details»
Immuno-Oncology at the Forefront of Cancer Medicine
Mar 2, 2025 Global initiatives are also working to expand immunotherapy access. The World Health Organization (WHO) and non-governmental organizations (NGOs) are advocating for …See details»
Immunoinformatics: Current trends and future directions - PMC
The World Health Organization (WHO) and Food and Agriculture Organization (FAO) proposed guidelines for evaluating allergenicity of genetically modified foods. According to the Codex …See details»
System vaccinology analysis of predictors and mechanisms of …
Jan 2, 2025 a, Study overview.A total of 50 healthy participants aged 21–45 years were randomized 2:1 to receive two doses 21 days apart of a monovalent, split-virion, inactivated …See details»